Affiliation: Mayo Clinic
- Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variantsMichael G Heckman
Section of Biostatistics, Mayo Clinic, Jacksonville, FL, USA Electronic address
Neurobiol Aging 35:266.e5-14. 2014..R1398H genotypes. Our results indicate that the association of LRRK2 p.R1398H with Parkinson's disease is independent of SNCA and MAPT variants, and vice versa, in Caucasian and Asian populations...
- Genetic variants associated with myocardial infarction in the PSMA6 gene and Chr9p21 are also associated with ischaemic strokeM G Heckman
Biostatistics Unit, Mayo Clinic, Jacksonville, FL 32224, USA
Eur J Neurol 20:300-8. 2013..This study evaluated whether genetic risk factors for CAD and MI also affect susceptibility to ischaemic stroke in Caucasians and African Americans...
- Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancerMichael G Heckman
Biostatistics Unit, Mayo Clinic Florida, Jacksonville, Florida 32224, USA
Prostate 72:1757-66. 2012..Herein, we provide the first evaluation of the ability of staining levels of the tumor based biomarkers MDM2, p16, and p53 to aid in prediction of biochemical recurrence (BCR) among men undergoing SRT for recurrent prostate cancer...
- Evaluation of the role of SNCA variants in survival without neurological diseaseMichael G Heckman
Biostatistics Unit, Mayo Clinic, Jacksonville, Florida, United States of America
PLoS ONE 7:e42877. 2012..This exploratory study examined whether SNCA variants may also promote successful aging as defined by survival without neurological disease...
- In vivo silencing of alpha-synuclein using naked siRNAJada Lewis
Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Mol Neurodegener 3:19. 2008..Genetic variability in SNCA contributes to risk of idiopathic Parkinson's disease (PD), possibly as a result of overexpression. SNCA downregulation is therefore a valid therapeutic target for PD...